HK1210777A1 - Quinazolinone derivatives as parp inhibitors parp - Google Patents
Quinazolinone derivatives as parp inhibitors parpInfo
- Publication number
- HK1210777A1 HK1210777A1 HK15111558.4A HK15111558A HK1210777A1 HK 1210777 A1 HK1210777 A1 HK 1210777A1 HK 15111558 A HK15111558 A HK 15111558A HK 1210777 A1 HK1210777 A1 HK 1210777A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- parp
- quinazolinone derivatives
- inhibitors
- quinazolinone
- derivatives
- Prior art date
Links
- AVRPFRMDMNDIDH-UHFFFAOYSA-N 1h-quinazolin-2-one Chemical class C1=CC=CC2=NC(O)=NC=C21 AVRPFRMDMNDIDH-UHFFFAOYSA-N 0.000 title 1
- 239000012661 PARP inhibitor Substances 0.000 title 1
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12006707 | 2012-09-26 | ||
| PCT/EP2013/002577 WO2014048532A1 (en) | 2012-09-26 | 2013-08-27 | Quinazolinone derivatives as parp inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1210777A1 true HK1210777A1 (en) | 2016-05-06 |
Family
ID=47002492
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK15111558.4A HK1210777A1 (en) | 2012-09-26 | 2015-11-24 | Quinazolinone derivatives as parp inhibitors parp |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US9388142B2 (pt) |
| EP (1) | EP2900643B1 (pt) |
| JP (1) | JP6276769B2 (pt) |
| KR (1) | KR102200628B1 (pt) |
| CN (1) | CN104662006B (pt) |
| AR (1) | AR092670A1 (pt) |
| AU (1) | AU2013324681B2 (pt) |
| BR (1) | BR112015006524A8 (pt) |
| CA (1) | CA2886000C (pt) |
| ES (1) | ES2654464T3 (pt) |
| HK (1) | HK1210777A1 (pt) |
| IL (1) | IL237840A (pt) |
| MX (1) | MX362855B (pt) |
| RU (1) | RU2650107C2 (pt) |
| SG (1) | SG11201502120XA (pt) |
| WO (1) | WO2014048532A1 (pt) |
| ZA (1) | ZA201502838B (pt) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2794627T3 (en) | 2011-12-22 | 2019-01-14 | Alios Biopharma Inc | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGUES THEREOF |
| MX346147B (es) | 2012-03-07 | 2017-03-09 | Inst Of Cancer Research: Royal Cancer Hospital (The) | Compuestos de 3-aril-5-substituido-isoquinolin-1-ona y su uso terapeutico. |
| US9441007B2 (en) | 2012-03-21 | 2016-09-13 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| USRE48171E1 (en) | 2012-03-21 | 2020-08-25 | Janssen Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| CN104395330B (zh) | 2012-05-25 | 2018-03-13 | 爱尔兰詹森科学公司 | 尿嘧啶基螺氧杂环丁烷核苷 |
| WO2014100505A1 (en) | 2012-12-21 | 2014-06-26 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| NO3044221T3 (pt) | 2013-09-11 | 2018-07-21 | ||
| JP6899323B2 (ja) | 2014-10-14 | 2021-07-07 | ラ ホーヤ インスティテュート オブ アレルギー アンド イミュノロジー | 低分子量タンパク質チロシンホスファターゼの阻害剤、及びその使用 |
| US10722484B2 (en) | 2016-03-09 | 2020-07-28 | K-Gen, Inc. | Methods of cancer treatment |
| CN107286169B (zh) * | 2016-04-05 | 2020-11-24 | 北京四环制药有限公司 | 端锚聚合酶抑制剂 |
| CN106432103A (zh) * | 2016-09-14 | 2017-02-22 | 信阳师范学院 | 一种喹唑酮类化合物及其制备方法 |
| WO2018204176A1 (en) * | 2017-05-01 | 2018-11-08 | Sanford Burnham Prebys Medical Discovery Institute | Inhibitors of low molecular weight protein tyrosine phosphatase (lmptp) and uses thereof |
| WO2019131798A1 (ja) * | 2017-12-27 | 2019-07-04 | 国立研究開発法人理化学研究所 | 新規ジヒドロキナゾリノン系化合物又はその薬理学的に許容される塩、及び細胞増殖阻害剤 |
| US20210060016A1 (en) * | 2017-12-27 | 2021-03-04 | Japanese Foundation For Cancer Research | Anticancer agent |
| CN114144401A (zh) * | 2019-08-28 | 2022-03-04 | 豪夫迈·罗氏有限公司 | 用于治疗和预防乙型肝炎病毒疾病的新型喹唑啉化合物 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3046871A1 (de) * | 1980-12-12 | 1982-07-22 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue chinazolinone, ihre herstellung und ihre verwendung als arzneimittel |
| DE3166627D1 (en) * | 1980-12-12 | 1984-11-15 | Thomae Gmbh Dr K | Pyrimidones, their preparation and medicines containing them |
| GB9404485D0 (en) | 1994-03-09 | 1994-04-20 | Cancer Res Campaign Tech | Benzamide analogues |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| IL125686A (en) | 1996-02-13 | 2002-11-10 | Zeneca Ltd | Quinazoline derivatives, processes for their preparation, pharmaceutical preparations containing them and their use in the manufacture of a drug with an anti-angiogenic effect and / or an effect of reducing vascular permeability |
| DE69709319T2 (de) | 1996-03-05 | 2002-08-14 | Astrazeneca Ab, Soedertaelje | 4-anilinochinazolin derivate |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| GB9702701D0 (en) | 1997-02-01 | 1997-04-02 | Univ Newcastle Ventures Ltd | Quinazolinone compounds |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| ATE404539T1 (de) | 1997-10-02 | 2008-08-15 | Eisai R&D Man Co Ltd | Kondensierte pyridinderivate |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| US7030123B2 (en) | 2000-05-31 | 2006-04-18 | Astrazeneca Ab | Indole derivatives with vascular damaging activity |
| JP2004502766A (ja) | 2000-07-07 | 2004-01-29 | アンギオジェン・ファーマシューティカルズ・リミテッド | 血管損傷剤としてのコルヒノール誘導体 |
| KR20030022264A (ko) | 2000-07-07 | 2003-03-15 | 앤지오젠 파마슈티칼스 리미티드 | 신생 혈관 형성 억제제인 콜치놀 유도체 |
| AU2003252314A1 (en) * | 2002-08-09 | 2004-02-25 | Kyorin Pharmaceutical Co., Ltd. | 4-substituted quinazoline-8-carboxyamide derivative and pharmaceutically acceptable addition salt thereof |
| MX2007010965A (es) * | 2005-03-09 | 2007-09-19 | Merck & Co Inc | Antagonistas de canales de calcio de tipo t de quinazolinona. |
| US8299256B2 (en) | 2007-03-08 | 2012-10-30 | Janssen Pharmaceutica Nv | Quinolinone derivatives as PARP and TANK inhibitors |
| WO2010106436A2 (en) | 2009-03-18 | 2010-09-23 | Resverlogix Corp. | Novel anti-inflammatory agents |
| TWI499418B (zh) | 2009-05-21 | 2015-09-11 | Nerviano Medical Sciences Srl | 異喹啉－１（２ｈ）－酮衍生物 |
| RU2013114710A (ru) * | 2010-09-03 | 2014-10-10 | Байер Интеллектуэль Проперти Гмбх | Замещенные конденсированные пиримидиноны и дигидропиримидиноны |
-
2013
- 2013-08-27 EP EP13756318.5A patent/EP2900643B1/en active Active
- 2013-08-27 US US14/431,632 patent/US9388142B2/en active Active
- 2013-08-27 CN CN201380050421.9A patent/CN104662006B/zh active Active
- 2013-08-27 JP JP2015533466A patent/JP6276769B2/ja active Active
- 2013-08-27 KR KR1020157010728A patent/KR102200628B1/ko active IP Right Grant
- 2013-08-27 ES ES13756318.5T patent/ES2654464T3/es active Active
- 2013-08-27 AU AU2013324681A patent/AU2013324681B2/en active Active
- 2013-08-27 SG SG11201502120XA patent/SG11201502120XA/en unknown
- 2013-08-27 CA CA2886000A patent/CA2886000C/en active Active
- 2013-08-27 BR BR112015006524A patent/BR112015006524A8/pt not_active Application Discontinuation
- 2013-08-27 MX MX2015003570A patent/MX362855B/es active IP Right Grant
- 2013-08-27 WO PCT/EP2013/002577 patent/WO2014048532A1/en active Application Filing
- 2013-08-27 RU RU2015115576A patent/RU2650107C2/ru active
- 2013-09-25 AR ARP130103430A patent/AR092670A1/es active IP Right Grant
-
2015
- 2015-03-19 IL IL237840A patent/IL237840A/en active IP Right Grant
- 2015-04-24 ZA ZA2015/02838A patent/ZA201502838B/en unknown
- 2015-11-24 HK HK15111558.4A patent/HK1210777A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2015535831A (ja) | 2015-12-17 |
| WO2014048532A1 (en) | 2014-04-03 |
| MX2015003570A (es) | 2015-06-22 |
| AR092670A1 (es) | 2015-04-29 |
| IL237840A (en) | 2017-05-29 |
| SG11201502120XA (en) | 2015-04-29 |
| EP2900643B1 (en) | 2017-09-27 |
| US9388142B2 (en) | 2016-07-12 |
| JP6276769B2 (ja) | 2018-02-07 |
| CN104662006B (zh) | 2017-10-24 |
| RU2650107C2 (ru) | 2018-04-09 |
| CN104662006A (zh) | 2015-05-27 |
| CA2886000C (en) | 2020-11-10 |
| US20150239850A1 (en) | 2015-08-27 |
| ZA201502838B (en) | 2017-11-29 |
| AU2013324681A1 (en) | 2015-05-07 |
| ES2654464T3 (es) | 2018-02-13 |
| CA2886000A1 (en) | 2014-04-03 |
| BR112015006524A8 (pt) | 2019-08-20 |
| RU2015115576A (ru) | 2016-11-20 |
| MX362855B (es) | 2019-02-20 |
| AU2013324681B2 (en) | 2017-08-10 |
| BR112015006524A2 (pt) | 2017-07-04 |
| KR102200628B1 (ko) | 2021-01-08 |
| KR20150063474A (ko) | 2015-06-09 |
| EP2900643A1 (en) | 2015-08-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20181429T8 (hr) | Novi derivati benzimidazola kao inhibitori kinaze | |
| HK1210777A1 (en) | Quinazolinone derivatives as parp inhibitors parp | |
| HK1210775A1 (en) | Imidazotriazinecarbonitriles useful as kinase inhibitors | |
| HK1208442A1 (en) | Substituted pyrrolopyrimidinylamino-benzothiazolones as mknk kinase inhibitors mknk | |
| HK1211027A1 (en) | Pyrrolotriazinone derivatives as pi3k inhibitors pi3k | |
| HRP20160735T1 (hr) | Derivati tetrahidro-kinazolinona kao inhibitori tank i parp | |
| ZA201409497B (en) | Tetrahydroquinazolinone derivatives as parp inhibitors | |
| HK1213252A1 (zh) | 雙環二氫吡啶酮激酶抑制劑 | |
| SG11201500973WA (en) | Amino-quinolines as kinase inhibitors | |
| HK1212331A1 (en) | 4-carboxamido-isoindolinone derivatives as selective parp-1 inhibitors parp-1 4-- | |
| HK1209422A1 (en) | Fbxo3 inhibitors fbxo3 | |
| EP2847186A4 (en) | SUBSTITUTED AMINOCHINAZOLINES USE AS CHINESE HEMMER | |
| HK1213181A1 (zh) | 雙環氧雜內酰胺激酶抑制劑 | |
| SG11201501212QA (en) | Quinazoline derivatives and uses thereof as apoptosis inhibitor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20230825 |